Fisher Stewart
Known title: Chief Scientific OfficerCIK: 0001824863
Associated companies
Transaction History
| CCCC | ▲ Buy | Option Exercise | 2,250 | — | 9/16/2024 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 661 | $4K | 9/16/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 27,300 | $0 | 2/14/2024 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 2,255 | $15K | 2/13/2024 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 2,250 | — | 8/30/2023 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 661 | $2K | 8/30/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 26,000 | $0 | 2/13/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 25,928 | $129K | 4/12/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 2,156 | $8K | 4/12/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 17,786 | $66K | 12/8/2021 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 2,373 | $5K | 12/8/2021 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 403 | $2K | 12/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.